stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Net income
Scholar Rock Holding Corporation's net income for fiscal 2025 was −$377.9M, compared with −$246.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$408.6M. Over the past ten years it has ranged from −$377.9M (fiscal 2025) to −$16.2M (fiscal 2016) — the current reading is the lowest in ten years. Net income has fallen for 9 consecutive fiscal years. Scholar Rock Holding Corporation ranks 574th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$377.9M | — |
| FY2024 | −$246.3M | — |
| FY2023 | −$165.8M | — |
| FY2022 | −$134.5M | — |
| FY2021 | −$131.8M | — |
| FY2020 | −$86.5M | — |
| FY2019 | −$51.0M | — |
| FY2018 | −$49.3M | — |
| FY2017 | −$25.0M | — |
| FY2016 | −$16.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$109.9M | — |
| Mar 2026 | −$105.5M | — |
| Dec 2025 | −$91.0M | — |
| Sep 2025 | −$102.2M | — |
| 34 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| PTCT PTC Therapeutics, Inc. compare | −$106.0M |
| MANE Veradermics Incorporated compare | −$136.4M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| ERAS Erasca, Inc. compare | −$287.2M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| SRRK Scholar Rock Holding Corporation | −$408.6M |
| IMVT Immunovant, Inc. compare | −$538.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SRRK
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement